New drug combo aims to shrink lung tumors before surgery in targeted trial
NCT ID NCT07153770
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 2 trial tests whether the targeted drug bozitinib, combined with standard chemotherapy, can shrink tumors before surgery in people with stage IIA to IIIC non-small cell lung cancer that has a specific MET gene change. About 34 participants will receive the drug combo for 8 weeks, then have surgery to remove any remaining cancer. The main goal is to see how many patients have a major response in their tumor tissue after treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Bozitinib (a targeted cancer drug) combined with standard chemotherapy
What this could lead to
If successful, this could offer a more effective way to shrink MET-altered lung cancers before surgery, potentially improving long-term survival and reducing recurrence.
What could go wrong
This is a small, early-phase trial with only 34 participants. The combination may cause significant side effects, and it is not yet known if it will work better than standard treatment alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••